100mg ritalin per dag

I took mg of concerta at once 5 pills 36mg then around 12 hours later I took another mg for mg total in around 24 hours give or take I of course was speeding but later on I felt sick and weird but I didn't throw up or any thing and then I was fine and stuff The reason you didn't feel as sped is because concerta is an extended release version of methylphendiate, whereas typcial ritalin is in tablet form that just hits you right away.

BIG difference in terms of chance of OD. N-o- Yes I can get them with a snap of my fingers but nope I think a better but still bad example would be non time release and time release adderall The beads are still good if you crush them to a dust with your pill crusher and snort them But the non time release are just better They taste better the drip is better snorting them is better crushing them is better tormentedpunk88 i thought you couldnt get high on concerta?

N-o- Yes I can get them with a snap of my fingers but nope I think a better but still bad example would be non time release and time release adderall The beads are still good if you crush them to a dust with your pill crusher and snort them But the non time release are just better They taste better the drip is better snorting them is better crushing them is better Wow, come on man, get ahold of yourself.

I was using the drug oxycontin to try and explain to you the concept of time-release. I was not implying that you have ever done or would ever do oxycontin. The funny thing is that the websites including this phrase are invariably the ones discouraging use.

I took one 20mg cap and felt really good the first day. I did the same the next day. And without changing anything, the third day I took my normal dose and I felt sick to my stomach - a constant sick feeling in my gut, meaning I never had the feeling I was about to yak. I did eat some food so you can rule out not eating anything which makes me wonder why this happens.

Ok so the 4th day, being dumb and after reading these posts plus the sick feeling I was pretty sure would set in, I crushed the beads up and sniffed them. Only 20mg, not exactly because I lost or so beads. I felt real good like the first time I dosed Ritalin. This lasted for about mins. When I sniffed, it did burn but not badly. The systemic clearance is 0.

Food Effects Administration times relative to meals and meal composition may need to be individually titrated. When Ritalin LA was administered with a high fat breakfast to adults, Ritalin LA had a longer lag time until absorption began and variable delays in the time until the first peak concentration, the time until the interpeak minimum, and the time until the second peak. The effect of a high fat lunch was not examined.

There were no differences in the pharmacokinetics of Ritalin LA when administered with applesauce, compared to administration in the fasting condition. There is no evidence of dose dumping in the presence or absence of food.

Fifteen of these children were between 10 and 12 years of age. The time until the between peak minimum, and the time until the second peak were delayed and more variable in children compared to adults. After a mg dose of Ritalin LA, concentrations in children were approximately twice the concentrations observed in 18 to 35 year old adults.

This higher exposure is almost completely due to the smaller body size and total volume of distribution in children, as apparent clearance normalized to body weight is independent of age.

There were no apparent gender differences in the pharmacokinetics of methylphenidate between healthy male and female adults when administered Ritalin LA. Ritalin LA has not been studied in renally-impaired patients. Ritalin LA has not been studied in patients with hepatic insufficiency. Hepatic insufficiency is expected to have minimal effect on the pharmacokinetics of methylphenidate since it is metabolized primarily to ritalinic acid by nonmicrosomal hydrolytic esterases that are widely distributed throughout the body.

The doses used were the optimal doses established in a previous individual dose titration phase. The change from baseline of the CADS-T scores during the last week of treatment was analyzed as the primary efficacy parameter.

Patients treated with Ritalin LA showed a statistically significant improvement in symptom scores from baseline over patients who received placebo. The symptoms must cause clinically significant impairment, e. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: The Combined Types requires both inattentive and hyperactive-impulsive criteria to be met.

Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV characteristics. Need for Comprehensive Treatment Program Ritalin LA is indicated as an integral part of a total treatment program for ADHD that may include other measures psychological, educational, social for patients with this syndrome.

Drug treatment may not be indicated for all children with this syndrome. Appropriate educational placement is essential and psychosocial intervention is often helpful. Hypersensitivity to Methylphenidate Ritalin LA is contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product.

Glaucoma Ritalin LA is contraindicated in patients with glaucoma. Monoamine Oxidase Inhibitors Ritalin LA is contraindicated during treatment with monoamine oxidase inhibitors, and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor hypertensive crises may result.

Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug. Adults Sudden death, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD.

Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs. Psychiatric Adverse Events Preexisting Psychosis Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.

Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate.

In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0. Aggression Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD. Although there is no systematic evidence that stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.

Long-Term Suppression Of Growth Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months to the ages of 10 to 13 years , suggests that consistently medicated children i.

Published data are inadequate to determine whether chronic use of amphetamines may cause a similar suppression of growth, however, it is anticipated that they likely have this effect as well. Therefore, growth should be monitored during treatment with stimulants, and patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted. Seizures There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures.

In the presence of seizures, the drug should be discontinued. Priapism Prolonged and painful erections, sometimes requiring surgical intervention, have been reported with methylphenidate products in both pediatric and adult patients. Priapism was not reported with drug initiation but developed after some time on the drug, often subsequent to an increase in dose. Priapism has also appeared during a period of drug withdrawal drug holidays or during discontinuation.

Patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention. Effects of peripheral vasculopathy, including Raynaud's phenomenon , were observed in postmarketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment.

Signs and symptoms generally improve after reduction in dose or discontinuation of drug. Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation e. Visual Disturbance Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.

Tags: omeprazole 20mg tab perrigo voltaren 75mg 3ml oldatos injekció xanax barsmg oxycodone 10mg np 12